Literature DB >> 10766424

Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation.

K Murakami1, T Matsuura, S Hasumura, S Nagamori, Y Yamada, I Saiki.   

Abstract

We examined the relationship between the expression of retinoic acid receptor-alpha (RAR-alpha) and upregulation of insulin-like growth factor binding protein-3 (IGFBP-3) in the retinoid-induced inhibition of hepatocellular carcinoma (HCC) cell proliferation. HCC cell lines showed a marked expression of RAR-alpha, whereas the expression levels of RAR-beta and RAR-gamma were relatively lower. An RAR-alpha agonist significantly inhibited the HCC cell proliferation both in vitro and in vivo. The RAR-alpha expression closely related to the upregulation of IGFBP-3 as compared with RAR-beta or RAR-alpha expressions. RAR-alpha agonist would be beneficial to inhibit the growth of HCC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766424     DOI: 10.1016/s0304-3835(99)00410-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Tamibarotene: a new hope for therapeutic efficacy in hepatocellular carcinoma patients.

Authors:  Junliang Fu; Ji-Yuan Zhang; Fu-Sheng Wang
Journal:  Hepatol Int       Date:  2013-12-28       Impact factor: 6.047

2.  The effects of retinoic acid on the insulin-like growth factor axis in primary tissue culture from hyperparathyroidism.

Authors:  Chris K M Wong; Teresa Lai; Jeffrey M P Holly; Malcolm H Wheeler; Claire E H Stewart; John R Farndon
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

3.  Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Shun-Yuan Jiang; Jung-Mao Chou; Fur-Jiang Leu; Yu-Yen Hsu; Yu-Lung Shih; Jyh-Cherng Yu; Meei-Shyuan Lee; Rong-Yaun Shyu
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

4.  An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma.

Authors:  Fumihiko Kanai; Shuntaro Obi; Shigetoshi Fujiyama; Shuichiro Shiina; Hideyuki Tamai; Hitoshi Mochizuki; Yukihiro Koike; Jun Imamura; Takayoshi Yamaguchi; Isamu Saida; Osamu Yokosuka; Masao Omata
Journal:  Hepatol Int       Date:  2013-07-25       Impact factor: 9.029

Review 5.  Retinoic Acids in the Treatment of Most Lethal Solid Cancers.

Authors:  Lara Costantini; Romina Molinari; Barbara Farinon; Nicolò Merendino
Journal:  J Clin Med       Date:  2020-01-28       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.